

Gastrointestinal mediation of glucose homeostasis and postprandial cardiovascular risk

A thesis submitted by

Dr Sony Sebastian Thazhath

MBBS, MD

For the degree of

Doctor of Philosophy

Discipline of Medicine

University of Adelaide

February 2016

Table of Contents

Table of Contents	II
THESIS SUMMARY.....	XII
DECLARATION.....	XVIII
ACKNOWLEDGEMENTS	XX
PUBLICATIONS ARISING FROM THE THESIS	XXIII
STATEMENT OF AUTHORSHIP	25
CHAPTER 1. GLUCOSE ABSORPTION IN SMALL INTESTINAL DISEASES.....	50
1.1 Abstract.....	50
1.2 Introduction	50
1.3 Physiology of glucose absorption.....	51
1.3.1 Gastrointestinal motility	51
1.3.2 Digestion of carbohydrates.....	53
1.3.3 Effects of sweet ‘tasting’ by the intestine.....	54
1.3.4 Glucose transport across the small intestinal mucosa	56
1.4 Quantification of glucose absorption	59
1.5 Diseases affecting glucose availability in the small intestine	61
1.5.1 Disorders of gastric motility.....	61
1.5.2 Bariatric surgery	62
1.5.3 Dumping Syndrome	63
1.6 Disorders of carbohydrate digestion	64
1.7 Disorders of glucose transporters in the intestinal mucosa.....	65

1.8 Glucose absorption in critical illness	66
1.9 Glucose absorption in short gut syndrome.....	68
1.10 Glucose absorption in type 2 diabetes	70
1.10.1 Disordered gastric motility	70
1.10.2 Disordered carbohydrate digestion.....	71
1.10.3 Disorders of intestinal ‘sweet tasting’	71
1.10.4 Disorders of glucose transporters.....	72
1.11 Expert Commentary	73
1.12 Five year view.....	73
1.13 Key issues	74
Figure 1.....	75
Figure 2.....	76

CHAPTER 2. DIABETIC GASTROPARESIS – RECENT INSIGHTS INTO

PATHOPHYSIOLOGY, AND IMPLICATIONS FOR MANAGEMENT.	78
2.1 Abstract.....	78
2.2 Introduction	78
2.3 Epidemiology	79
2.4 Physiology of normal gastric motility	80
2.5 Motor abnormalities in diabetic gastroparesis.....	82
2.6 Etiology and natural history of symptoms in diabetic gastroparesis.....	83
2.7 Pathophysiology of diabetic gastroparesis	83
2.7.1 Role of nitric oxide as an inhibitory neurotransmitter in diabetic gastroparesis.....	84
2.7.2 Role of ICC loss or dysfunction in diabetic gastroparesis.....	85
2.8 Diagnosis	88
2.8.1 Scintigraphy	89

Figure 1.....	90
2.8.2 ¹³ CO ₂ Breath test	91
2.8.3 Wireless Motility Capsule (WMC or “Smart Pill”).....	91
2.8.4 Ultrasonography.....	92
2.8.5 Magnetic Resonance Imaging (MRI)	93
2.8.6 Electrogastrography	93
2.9 Assessment of severity of gastroparesis	94
2.10 Management	94
2.10.1 Glycemic control and gastroparesis.....	95
2.10.2 Dietary modification in diabetic gastroparesis.....	98
2.10.3 Prokinetics	99
2.10.4 Antiemetics	102
2.10.5 Pain management.....	102
2.10.6 Intrapyloric botulinum injection	103
2.10.7 Gastric electric stimulation (GES).....	103
2.10.8 Surgical treatment.....	105
2.10.9 Stem Cells.....	105
2.10.10 Psychological disorders and gastroparesis.....	106
2.10.11 Alternative therapies.....	106
2.11 Prognosis of diabetic gastroparesis	107
Figure 2.....	108
2.12 Expert commentary.....	109
2.13 Five-year view	109
CHAPTER 3. METHODOLOGY	111
3.1 Introduction	111

3.2 Approval by the ethics committee.....	111
3.3 Recruitment of study subjects	112
3.4 Gastrointestinal symptom questionnaires	112
3.5 Autonomic nerve function.....	112
3.6 Flow mediated dilatation.....	113
3.7 Gastric emptying.....	114
3.8 Intraduodenal infusion	115
3.9 Measurements of duodenal motility and flow events	115
3.10 Small intestinal transit.....	117
3.11 Appetite perception and energy intake	118
3.11.1 Visual analog scales (VAS).....	118
3.11.2 Energy intake	118
3.12 Assessment of intestinal glucose absorption.....	119
3.12.1 3-O-methylglucose (3-OMG).....	119
3.13 Biochemical measurements.....	119
3.13.1 Blood glucose	119
3.13.2 Glucagon like-peptide 1 (GLP-1).....	120
3.13.3 Glucose-dependent insulintropic peptide (GIP)	120
3.13.4 Insulin.....	120
3.13.5 C-peptide.....	120
3.13.6 Glucagon.....	121
3.14 Statistical analysis	121
3.15 Conclusions	121

CHAPTER 4. CHANGES IN MEAL COMPOSITION AND DURATION AFFECT

POSTPRANDIAL ENDOTHELIAL FUNCTION IN HEALTHY HUMANS	122
--	------------

4.1 Abstract	122
4.2 Introduction	123
4.3 Methods	125
4.3.1 Subjects	125
4.3.2 Protocol.....	125
4.4 Measurements	126
4.4.1 Flow mediated dilatation and heart rate.....	126
4.4.2 Blood glucose and serum insulin concentrations.....	127
4.4.3 Gastric emptying	128
4.5 Statistical analysis	128
4.6 Results	129
4.6.1 Gastric emptying	130
4.6.2 Blood glucose concentrations	130
Figure 1.....	131
Figure 2.....	132
Table 1:	133
4.6.3 Serum insulin concentrations	134
4.6.4 Serum insulin to blood glucose ratio (I/G ratio).....	134
4.6.5 FMD.....	135
4.6.6 Heart rate	135
4.6.7 Relationships between variables.....	136
4.7 Discussion	136

CHAPTER 5: THE GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONIST, EXENATIDE, INHIBITS SMALL INTESTINAL MOTILITY, FLOW, TRANSIT AND

**ABSORPTION OF GLUCOSE IN HEALTH AND TYPE 2 DIABETES: A RANDOMISED
CONTROLLED TRIAL 143**

5.1 Abstract 143

5.2 Introduction 144

5.3 Methods 147

5.3.1 Subjects 147

5.3.2 Protocol 148

5.3.3 Measurements 150

5.3.4 Statistical analysis 151

5.3.5 Study approval 152

5.4 Results 153

Figure 1 154

Figure 2 155

Figure 3 156

Figure 4 157

Figure 5 158

Table 1 159

Table 2 160

5.4.1 Duodenal pressure waves and flow events 161

5.4.2 Small intestinal transit 162

5.4.3 Blood glucose concentrations (Figure 3A and B and Table 2) 162

5.4.4 Serum 3-OMG concentration 163

5.4.5 Serum insulin concentrations 163

5.4.6 Plasma C-peptide concentrations 164

5.4.7 Gastrointestinal sensations 165

5.4.8 Relationships between variables.....	166
5.5 Discussion	166
 CHAPTER 6: ACUTE EFFECTS OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)	
RECEPTOR AGONIST, EXENATIDE, ON BLOOD PRESSURE AND HEART RATE	
RESPONSES TO INTRADUODENAL GLUCOSE INFUSION IN TYPE 2 DIABETES: A	
RANDOMISED CONTROLLED TRIAL.	
	173
6.1 Abstract.....	173
6.2 Introduction	174
6.3 Patients and Methods.....	175
6.3.1 Subjects.....	175
6.3.2 Protocol	175
6.3.3 Calculations and statistical analysis	176
6.4 Results	177
6.4.1 Systolic, diastolic and mean arterial blood pressure and heart rate	177
6.4.2 Blood glucose and serum insulin	178
6.4.3 Nausea.....	178
6.4.4 Duodenal motility index.....	178
6.4.5 Relationships between outcome measures.....	178
6.5 Discussion	179
 CHAPTER 7: EFFECTS OF HYDROXYCITRATE (HCA) ON INTESTINAL GLUCOSE	
ABSORPTION AND INCRETIN RELEASE IN HEALTHY SUBJECTS AND IN TYPE 2	
DIABETES.....	
	183

7.1 Abstract	183
7.2 Introduction	184
7.3 Experimental methods	186
7.3.1 Subjects	186
7.3.2. Protocol.....	187
7.3.3 Measurements.....	188
7.3.4 Calculations and statistical analysis.....	189
7.4 Results	190
7.4.1 Blood glucose.....	190
Figure 1:.....	191
Figure 2:.....	192
7.4.2 Serum 3-OMG.....	193
7.4.3 Plasma insulin	193
7.4.4 Beta cell function, insulin sensitivity and insulin resistance	194
Table 1	195
Table 2	197
7.4.5 Plasma glucagon	198
7.4.6 Plasma GIP	198
7.4.7 Plasma total GLP-1.....	199
7.4.8 Gastrointestinal sensations.....	199
7.5 Discussion	199

CHAPTER 8: EFFECTS OF 5 WEEKS RESVERATROL SUPPLEMENTATION ON GLP-1 SECRETION, GASTRIC EMPTYING, AND POSTPRANDIAL GLYCEMIA IN PATIENTS WITH TYPE 2 DIABETES	204
8.1 Abstract	204

8.2 Introduction	205
8.3 Methods.....	207
8.3.1 Subjects	207
8.3.2 Protocol.....	207
8.3.3 Measurements	209
8.3.4 Calculations and statistical analysis.....	209
8.4 Results	210
8.4.1 Plasma total GLP-1 concentrations.....	210
8.4.2 Blood glucose concentrations	211
8.4.3 HbA1c, gastric emptying, energy intake, and body weight.....	211
Figure 1.....	212
Figure 2.....	213
Table 1	214
8.5 Discussion	215
 CHAPTER 9: COMPARATIVE EFFECT OF INTRADUODENAL AND INTRAJEJUNAL GLUCOSE INFUSION ON THE GUT-INCRETIN AXIS RESPONSE IN HEALTHY MALES	
MALES	219
9.1 Abstract.....	219
9.2 Introduction	220
9.3 Subjects and methods	220
9.4 Results	222
Table 1	224
Figure 1.....	225
9.5 Conclusion	226

CHAPTER 10: MECHANISM OF INCREASE IN PLASMA INTACT GLP-1 BY METFORMIN IN TYPE 2 DIABETES: STIMULATION OF GLP-1 SECRETION OR REDUCTION IN PLASMA DPP-4 ACTIVITY?	229
10.1 Abstract	229
10.2 Introduction.....	229
10.3 Subjects and methods.....	230
10.4 Results.....	232
Figure 1.....	233
Table 1	234
10.5 Conclusion	235
CHAPTER 11: CONCLUSION	237
BIBLIOGRAPHY	242

THESIS SUMMARY

In the majority of patients with type 2 diabetes, who have reasonably good glycemic control (HbA_{1C} ~7.5% or less), it is postprandial glycemia which predominates over fasting blood glucose in contributing to HbA_{1C}; postprandial glycemia may therefore represent an independent risk factor for diabetic complications and adverse cardiovascular events (Monnier et al., 2003). Also, at the same HbA_{1C} level, subjects with larger fluctuations in the blood glucose levels postprandially carry a higher cardiovascular risk (Del Prato, 2002b). The magnitude of postprandial glycemic excursions is largely determined by the rate of gastric emptying of nutrients to the small intestine which in turn regulates various metabolically important neurohumoral responses set off mainly by the release of incretin hormones from the enteroendocrine cells of the intestine. Conversely, acute glycemic excursions can regulate gastric emptying through feedback mechanisms. This thesis highlights the pivotal role of the upper gastrointestinal tract in the regulation of postprandial glycemia and attendant cardiovascular risks in health and type 2 diabetes, and the capacity for interventions aimed at modulation of upper gut function to be effective in the treatment of diabetes. Following is a brief outline of the experimental studies described in this thesis:

1. Changes in meal composition and duration affect postprandial endothelial function in healthy humans

Impaired endothelial function is now well-recognized as a forerunner of atherosclerosis (Juonala et al., 2004), and is predictive of long-term adverse cardiovascular outcomes (Vogel, 2001). The endothelial dysfunction after an oral glucose load is related to the degree of rise in blood glucose in both health and type 2 diabetes (Title et al., 2000, Kawano et al., 1999), with the duration of dysfunction being greater in the latter (Akbari et al., 1998). The rate of gastric emptying is a major determinant of postprandial glycaemic increments (Chaikomin et al., 2006, Marathe et al., 2013) and modulating gastric emptying and/or nutrient absorption from the upper gut can be achieved non-pharmacologically by modifying the composition of a meal, for example by adding soluble fiber such as guar gum (Holt et al., 1979, Torsdottir et al., 1989), or by decreasing the rate of meal ingestion (Zhu et al., 2013). Though the effects of such dietary manipulations on glycemia have been described previously, their influence on postprandial endothelial function had not been investigated. We therefore evaluated the effects of dietary modifications designed to slow gastric emptying and/or small intestinal nutrient absorption on postprandial endothelial function in healthy humans.

2. The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in health and type 2 diabetes: a randomised controlled trial.

The presence of glucose in the small intestine stimulates the release of several peptides, including glucagon-like peptide-1 (GLP-1) (Schirra et al., 1996); the latter has a critical role in determining postprandial insulin and glycemic responses, mainly via its ability to slow gastric emptying and regulate nutrient delivery to the small intestine, though other factors such as its insulinotropic property could also be involved. Lately, GLP-1 receptor agonists have been used widely in the treatment of patients with type 2 diabetes, (Holst and Gromada, 2004, Elahi et al., 1994). Exenatide belongs to this class of medications and is resistant to degradation by the plasma enzyme di-peptidyl peptidase-IV (DPP-IV) that rapidly degrades endogenous GLP-1. Previous studies in healthy humans have demonstrated that intravenous exogenous GLP-1 slows gastric emptying (Little et al., 2006b, Nauck et al., 1997b), but the effects of GLP-1, or agonists of its receptor, on small intestinal flow events and transit have not yet been evaluated in humans. Data from animal studies have shown that exogenous GLP-1 inhibits small intestinal motility and transit (Tolessa et al., 1998b, Tolessa et al., 1998a), which could represent an additional mechanism in the lowering of postprandial glycemia. This chapter describes the effects of the GLP-1 receptor agonist, exenatide on duodenal pressure waves, flow events, small intestinal transit time, and the rate of small intestinal glucose absorption in healthy humans as well as in those with type 2 diabetes.

3. Effects of glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, on blood pressure and heart rate in response to intraduodenal glucose infusion in type 2 diabetes: a randomised controlled trial.

It is well recognised that the magnitude of postprandial hypotension depends largely on the rate of gastric emptying (Trahair et al., 2012b); hence glucagon-like peptide-1 (GLP-1) receptor stimulation, which slows gastric emptying, could potentially be used as a treatment for postprandial hypotension. As exogenous GLP-1 has been found to increase blood pressure in some human studies, albeit not consistently (Edwards et al., 1998, Halbirk et al., 2010, Bharucha et al., 2008), and attenuate the hypotensive effect of both oral (Trahair et al., 2015) and intraduodenal (Trahair et al., 2014b) glucose loads, mechanisms other than just slowing of gastric emptying could potentially be involved. In this chapter, we present the effects of an intravenous infusion of a GLP-1 receptor agonist, exenatide, on systolic, diastolic and mean arterial blood pressure, and heart rate, measured in the course of Study 2 (above), during and after the intraduodenal glucose infusion.

4. Effects of hydroxycitrate (HCA) on intestinal glucose absorption and incretin release in healthy subjects and in type 2 diabetes.

It is now well-recognised that patients with greater fluctuations in blood glucose carry a greater cardiovascular risk than those with lesser excursions, even if HbA_{1c} levels are similar (Del Prato, 2002a). Therefore, there has been an emerging interest in exploring the therapeutic potential of inhibiting/delaying postprandial small intestinal carbohydrate absorption in order to dampen the glycemic spikes (Qualmann et al., 1995). Extracts from the fruit *Garcinia cambogia*, in which hydroxycitric acid (HCA) is the active ingredient, have been widely marketed for weight loss, but may also reduce postprandial

glycemia. The latter claim is based mainly on findings from rodent studies, where HCA was associated with a delay in glucose absorption, and stimulation of GLP-1 release from the distal gut. In this chapter, we describe the effects of small intestinal pre-treatment with HCA on glucose absorption and incretin release in healthy humans and in patients with diet-controlled type 2 diabetes.

5. Effects of 5 weeks resveratrol supplementation on GLP-1 secretion, gastric emptying, and postprandial glycemia in patients with type 2 diabetes.

Resveratrol, a phytoalexin, found in plant foods including red grapes, improves glycemic control in experimental animals with type 2 diabetes by uncertain mechanisms (Vang et al., 2011) and could be attractive as a potential therapy for type 2 diabetes in humans because it is safe and relatively inexpensive. In a high fat diet mouse model of diabetes, supplementation with resveratrol for 5 weeks was associated with a reduction in the glycemic excursion after an oral glucose tolerance test, together with an enhanced insulin response and substantially increased concentrations of GLP-1 in the portal vein (Dao et al., 2011), as well as increases in the proglucagon mRNA and GLP-1 content in the colon. However, effects of resveratrol on GLP-1 secretion have not previously been evaluated in humans with diabetes. This chapter describes the effects of 5 weeks of resveratrol supplementation on GLP-1 secretion, gastric emptying, and postprandial glycemia in patients with diet-controlled type 2 diabetes.

6. Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males

Bariatric surgical procedures such as the Roux-en-Y gastric bypass are known to result in improvements in glycemic control in patients with type 2 diabetes, which is associated with an enhanced incretin response. In this chapter, we examined whether bypassing the duodenum would elicit a greater response of the gut-incretin axis to small intestinal glucose infusion, by comparing plasma GLP-1, GIP, insulin and glucagon, and blood glucose responses to a standardised glucose infusion into the proximal jejunum and duodenum in healthy humans.

7. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity?

The critical role of GLP-1 in glucose homeostasis is being increasingly recognised. In this chapter, we describe the effects of the widely used anti-diabetic medication, metformin, on total and intact GLP-1 concentrations, and on the activity of plasma dipeptidyl peptidase -4 (DPP-4), the enzyme responsible for the degradation of GLP-1, before and during an intraduodenal glucose infusion in patients with type 2 diabetes.

DECLARATION

Name: Sony Sebastian Thazhath

Program: Doctor of Philosophy

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint-award of this degree.

I give consent to this copy of my thesis when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

The author acknowledges that copyright of published works contained within this thesis resides with the copyright holder(s) of those works.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also

through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Signature:

12/02/2016

ACKNOWLEDGEMENTS

This thesis represents my original scientific work during the PhD course at the University of Adelaide. I acknowledge that a number of people wholeheartedly supported me academically, physically and morally to make this a reality.

I would like to express my sincere gratitude to my supervisors, Professor Chris Rayner and Professor Michael Horowitz, for their guidance and generous support, professionally as well as a personally, throughout the course of my PhD, making it a valuable and enjoyable experience. Their generosity and timely advice facilitated my attendance and presentations in major national as well as international scientific conferences, which helped me expand the horizons of my knowledge and experience.

I would like to say very special thanks for my principal supervisor, Professor Chris Rayner, who played a crucial role in the development of my academic life. I learned a lot from his professional as well as personal attributes and will always remember him as the most important person who made my PhD experience valuable.

I would also like to thank my colleagues in the Discipline of Medicine of the University of Adelaide, for their help, support and friendship, which made the PhD life a pleasant experience for me. I fondly remember the leisurely but valuable scientific discussions with Dr.Tongzhi Wu, Dr.Chinmay Marathe, Dr Robert Steinert, Ms Michelle Bound and Ms Helen Checklin and would like to give special thanks to each of them for their help and support. I also thank Dr.Linda Mignone, Mr Laurence Trahair and Ms Rachael Tippett who shared our office and created a very friendly work atmosphere and nurtured a productive work culture. I remember Dr Tim

Murphy with thanks for helping me get through the administrative hurdles of academic life in a friendly manner and with ease. Also my sincere thanks to Ms Judith Wishart and Mr Scott Standfield who got my laboratory samples analysed in a timely fashion and Ms Kylie Lange for her prompt and friendly statistical advice. I am also grateful to all other friendly staff in the Discipline of Medicine - Professor Gary Wittert, Professor Christine Feinle-Bisset, Associate Professor Leonie Heibronn, Professor Ian Chapman, Dr Tanya Little, Dr Natalie Luscombe-Marsh, Dr Miaoxin Chen, Dr Stign Soenen, Ms Amy Ryan, Ms Melanie Richards, Ms Elizabeth Westwood, Mr Geoge Hatzinikolas, Mr Raj Sardana, Ms Briohny Bartlett, Ms Penelope Fitzgerald, Ms Nicole Isaac, and Ms Victoria Tsagareli. I will always remember with gratitude, our late colleague, Antonietta Russo, who wholeheartedly assisted me in my studies even nearing her last days with a terminal illness.

I consider the opportunities to collaborate with Dr Richard Young in the Nerve Gut Laboratory and Mr Max Bellon in Nuclear Medicine at Royal Adelaide Hospital, extremely valuable. I extend my sincere gratitude to them.

I would also like to thank the University of Adelaide and the Rebecca L. Cooper Foundation for offering scholarship funding to support me during the course.

I feel greatly indebted to my parents, Sebastian and Annie, who have spent a major part of their life and energy for my personal as well as professional growth, which ultimately paved my way towards making this higher degree a reality.

Finally, a special mention about my wife, Milee and my children, Sebastian and Rhea who played a very important role in the completion of my PhD. I would like to express my heart-felt gratitude to them for their love, patience, understanding and encouragement.

PUBLICATIONS ARISING FROM THE THESIS

1. Thazhath SS, Wu T, Young RL, Horowitz M, Rayner CK. Glucose absorption in small intestinal diseases. *Expert Rev Gastroenterol Hepatol*. 2014 Mar;8(3): 301-12.
2. Thazhath SS, Jones KL, Horowitz M, Rayner CK. Diabetic gastroparesis: recent insights into pathophysiology and implications for management. *Expert Rev Gastroenterol Hepatol*. 2013 Feb;7(2):127-39.
3. Thazhath SS, Wu T, Bound M, Checklin H, Jones KL, Willoughby S, Horowitz M, Rayner CK. Changes in meal composition and duration, affect postprandial endothelial function in healthy humans. *Am J Physiol Gastrointest Liver Physiol*. 2014 Dec 15;307(12):G1191-7.
4. Thazhath SS, Marathe CS, Wu T, Khoo J, Kuo P, Russo A, Checklin H, Bound MJ, Rigda RS, Jones KL, Horowitz M, Rayner CK. The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in health and type 2 diabetes: a randomised controlled trial. *Diabetes*. 2016 Jan;65(1):269-75.
5. Thazhath SS, Wu T, Bound MJ, Checklin H, Standfield S, Jones KL, Horowitz M, Rayner CK. Effects of intraduodenal hydroxycitrate on glucose absorption, incretin release and glycemia in response to intraduodenal glucose infusion in health and type 2 diabetes – a randomised controlled trial. *Nutrition*. 2016 May;32(5):553-9. doi: 10.1016/j.nut.2015.11.004.
6. Thazhath SS, Wu T, Bound MJ, Checklin H, Jones KL, Horowitz M, Rayner CK. Administration of resveratrol for five weeks has no effect on GLP-1 secretion, gastric emptying, or glycemic control in type 2 diabetes – a randomised controlled trial. *Am J Clin Nutr*. 2016 Jan;103(1):66-70. doi: 10.3945/ajcn.115.117440.
7. Wu T, Thazhath SS, Marathe CS, Bound MJ, Jones KL, Horowitz M, Rayner

CK. Comparative effect of intraduodenal and intrajejunal glucose infusion on the gut-incretin axis response in healthy males. *Nutr Diabetes*. 2015 May 18;5:e156.

8. Wu T, Thazhath SS, Marathe CS, Bound MJ, Jones KL, Horowitz M, Rayner CK. Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? *Diabetes Res Clin Pract*. 2014 Oct;106(1):e3-6.

Statements of Authorship

NOTE: Statements of authorship appear in the print copy of the thesis held in the University of Adelaide Library.